Asco 2023 preview – a microcap winner
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
Astellas doesn’t buy Apellis
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
Sanofi pumps up its Pompe portfolio with Maze deal
In licensing Maze’s oral contender, the group has made another bet against gene therapies.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
